Skip Navigation LinksHome > May 2014 - Volume 36 - Issue 4 > Taurolidine Specifically Inhibits Growth of Neuroblastoma Ce...
Journal of Pediatric Hematology/Oncology:
doi: 10.1097/MPH.0000000000000149
Online Articles: Original Articles

Taurolidine Specifically Inhibits Growth of Neuroblastoma Cell Lines In Vitro

Luckert, Christian MD; Eschenburg, Georg PhD; Roth, Beate; Appl, Birgit; Reinshagen, Konrad MD, PhD; Bergholz, Robert MD

Collapse Box

Abstract

Background:

Neuroblastoma is a common pediatric solid tumor with poor outcome for metastatic disease. Thus, novel therapeutic options are of main interest. The anti-neoplastic properties of taurolidine have been demonstrated on a variety of human cancer cells. However, data on neuroblastoma is lacking. Therefore, our aim was to evaluate the effect of taurolidine on growth of neuroblastoma cell lines.

Materials and Methods:

Neuroblastoma SK-N-BE(2)-M17 and SK-N-SH cells and nonmalignant human umbilical vein endothelial cells as controls were incubated with increasing concentrations of taurolidine (100, 250, 500 µM). Cell growth was examined after 12, 24, and 48 hours of exposure.

Results:

Inhibition of cell growth by taurolidine was seen in both malignant cell lines. When compared with human umbilical vein endothelial cells, the neuroblastoma cell lines were significantly more responsive to taurolidine.

Conclusions:

The observed negative impact on cell growth, highly distinctive in SK-N-BE(2)-M17 and SK-N-SH, implies a taurolidine-specific mode of action that appears dependent on differences on cellular and molecular level. Further investigations are warranted to evaluate its mechanism and probable clinical use.

Copyright © 2014 by Lippincott Williams & Wilkins

Login

Article Tools

Share

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.

Connect With Us

Twitter
twitter.com/JPHOonline

For additional oncology content, visit LWW Oncology Journals on Facebook.